Long Focus Capital Management LLC Takes Position in Bicycle Therapeutics plc (NASDAQ:BCYC)

Long Focus Capital Management LLC bought a new position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 543,092 shares of the company's stock, valued at approximately $7,603,000. Long Focus Capital Management LLC owned about 0.79% of Bicycle Therapeutics at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Barclays PLC boosted its stake in shares of Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after buying an additional 2,345 shares during the last quarter. Avior Wealth Management LLC bought a new position in Bicycle Therapeutics in the fourth quarter valued at approximately $57,000. China Universal Asset Management Co. Ltd. increased its position in shares of Bicycle Therapeutics by 30.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock worth $131,000 after purchasing an additional 2,191 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock worth $191,000 after purchasing an additional 1,782 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in shares of Bicycle Therapeutics by 35.7% in the 3rd quarter. Jane Street Group LLC now owns 20,180 shares of the company's stock valued at $457,000 after buying an additional 5,310 shares during the last quarter. Institutional investors own 86.15% of the company's stock.

Bicycle Therapeutics Stock Performance

Shares of BCYC opened at $8.73 on Wednesday. The firm's 50-day simple moving average is $9.31 and its 200 day simple moving average is $15.37. The firm has a market cap of $604.13 million, a P/E ratio of -2.65 and a beta of 1.40. Bicycle Therapeutics plc has a 52 week low of $6.10 and a 52 week high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.10. The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.47 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm's revenue for the quarter was down 30.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.16) earnings per share. As a group, equities analysts forecast that Bicycle Therapeutics plc will post -3.06 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on BCYC shares. HC Wainwright restated a "buy" rating and set a $33.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. Stephens reiterated an "equal weight" rating and issued a $15.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Finally, Needham & Company LLC reissued a "buy" rating and set a $30.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, April 9th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $29.14.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.